Article(id=1322631292714332417, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1322631228000424183, articleNumber=null, orderNo=null, doi=10.7501/j.issn.0253-2670.2026.18.021, pmid=null, cstr=null, oa=null, hot=0, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1774281600000, receivedDateStr=2026-03-24, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793269473483, onlineDateStr=2026-10-29, pubDate=null, pubDateStr=null, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793269473483, onlineIssueDateStr=2026-10-29, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793269473483, creator=13701087609, updateTime=1793269473483, updator=13701087609, issue=Issue{id=1322631228000424183, tenantId=1146029695717560320, journalId=1302319053441957962, year='2026', volume='57', issue='18', pageStart='7073', pageEnd='7500', issueExtLink='null', onlineDate='null', pubDate='1790524800000', pubDateStr='2026-09-28', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793269458054, creator='13701087609', updateTime=1793269548245, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322631606339228314, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1322631228000424183, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322631606339228315, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1322631228000424183, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=7334, endPage=7346, ext={EN=ArticleExt(id=1322631293012128003, articleId=1322631292714332417, tenantId=1146029695717560320, journalId=1302319053441957962, language=EN, title=Preparation, pharmacokinetics and protective effect on hepatic ischemia reperfusion injury of galangin-whey protein-nanoparticles, columnId=null, journalTitle=Chinese Traditional and Herbal Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=Objective To prepare galangin-whey protein-nanoparticles (Gal-WP-NPs), and study its oral pharmacokinetic behavior and protective effect on the hepatic ischemia reperfusion injury in vivo . Methods Single-factor experiments were conducted to investigate the effects of various formulation processes on Gal-WP-NPs. Box-Behnken design-response surface methodology (BBD-RSM) was used to obtain its optimal prescriptions. Entrapment efficiency, drug loading, particle size and ζ potential were determined. Gal-WP-NPs powder was prepared by freeze-drying method. Transmission electron microscopy (TEM) was used to observe the microstructure of Gal-WP-NPs. Galangin crystal in Gal-WP-NPs powder was analyzed by X-ray powder diffraction (XRPD). Solubility of galangin and Gal-WP-NPs powder were compared, and drug release behavior of Gal-WP-NPs in gastrointestinal fluid was determined. SD rats were administered galangin and Gal-WP-NPs via ig at a dose of 150 mg/kg (calculated as galangin), the main pharmacokinetic parameters and relative bioavailability of Gal-WP-NPs were calculated. The model of hepatic ischemia reperfusion injury was established, and then the protective effects of galangin and Gal-WP-NPs were compare on the hepatic ischemia reperfusion injury. Results Optimal formulation processes of Gal-WP-NPs: the volume ratio of the anti-solvent phase to the solvent phase was 15.40:1, the amounts ratio of whey protein to galangin was 15.05:1, and the ultrasonic power was 82.00 W. Envelopment efficiency, drug loading, particle size and ζ potential were (94.07 ± 0.98)%, (5.76 ± 0.09)%, (197.39 ± 4.46) nm and (-23.79 ± 0.75) mV, respectively. Gal-WP-NPs are spherical nanoparticles. Galangin existed as an amorphous state in Gal-WP-NPs powder. Solubility of galangin was significantly increased (P < 0.01), and the release process of Gal-WP-NPs in vitro conformed to the Weibull model. The peak time (t max ) of Gal-WP-NPs was delayed to (2.17 ± 0.64) h, half-life period (t 1/2 ) was increased to (5.11 ± 0.95) h, and oral relative bioavailability was increased to 6.58 times. Gal-WP-NPs significantly enhanced the protective effect of galangin on the hepatic ischemia reperfusion injury. Conclusion Gal-WP-NPs significantly increased the oral relative bioavailability of galangin and enhanced the protective effect on the hepatic ischemia reperfusion injury., authors=XUE Xiaofei1 , DONG Pengyuan2 , XU Mengya3 , WANG Panpan4 , authorsList=XUE Xiaofei, DONG Pengyuan, XU Mengya, WANG Panpan, authorCompany=1 Zhengzhou Health College, Zhengzhou 450064, China; 目的 制备高良姜素-乳清蛋白纳米粒（galangin-whey protein-nanoparticles，Gal-WP-NPs），考察其体内口服药动学行为及其对肝缺血再灌注损伤的保护作用。方法 单因素实验考察各个处方工艺对Gal-WP-NPs的影响。采用Box-Behnken设计-效应面法（Box-Behnken design-response surface methodology，BBD-RSM）得到Gal-WP-NPs最优处方工艺，测定Gal-WP-NPs包封率、载药量、粒径及ζ电位等。冷冻干燥法制备Gal-WP-NPs粉末，透射电子显微镜（transmission electron microscope，TEM）观察Gal-WP-NPs微观形貌，X射线粉末衍射（X-ray powder diffraction，XRPD）法分析Gal-WP-NPs中高良姜素晶型。比较高良姜素及Gal-WP-NPs溶解度，考察Gal-WP-NPs模拟胃肠液中的释药行为。按150 mg/kg（以高良姜素计）ig给予SD大鼠高良姜素和Gal-WP-NPs，计算主要药动学参数及Gal-WP-NPs相对生物利用度。建立SD大鼠肝脏缺血再灌注模型，比较高良姜素和Gal-WP-NPs对肝缺血再灌注损伤的保护作用。结果 Gal-WP-NPs最佳处方工艺：反溶剂相与溶剂相体积比为15.40∶1，乳清蛋白与高良姜素用量比为15.05∶1，超声功率为82.00 W。Gal-WP-NPs包封率、载药量、粒径和ζ电位分别为（94.07±0.98）%、（5.76±0.09）%、（197.39±4.46）nm和（-23.79±0.75）mV。Gal-WP-NPs呈类球形纳米粒，高良姜素在Gal-WP-NPs粉末中以无定形状态存在，溶解度得到极显著提高（P ＜0.01），Gal-WP-NPs体外释药行为符合Weibull模型。Gal-WP-NPs达峰时间（t max）延后至（2.17±0.64）h，半衰期（t ₁/₂）增加至（5.11±0.95）h，口服相对生物利用度提高至6.58倍。Gal-WP-NPs极大提高了高良姜素对肝缺血再灌注损伤的保护作用。结论 Gal-WP-NPs显著增加了高良姜素口服相对生物利用度，增强了高良姜素对对肝缺血再灌注损伤的保护作用。, authors=薛晓菲1 , 董鹏远2 , 许梦雅3 , 王盼盼4 , authorsList=薛晓菲, 董鹏远, 许梦雅, 王盼盼, authorCompany=1 郑州健康学院, 河南 郑州 450064;
中草药
|药剂与工艺
2026
, 57
(18) :
7334
-7346
高良姜素-乳清蛋白纳米粒的制备、药动学及其对肝缺血再灌注损伤的保护作用
全屏
薛晓菲1 , 董鹏远2 , 许梦雅3 , 王盼盼4
作者信息
1 郑州健康学院, 河南 郑州 450064;
作者简介:
薛晓菲: 薛晓菲（1989—），女，学士，讲师，研究方向为临床药学及康复治疗。E-mail:yibing0401@126.com
Preparation, pharmacokinetics and protective effect on hepatic ischemia reperfusion injury of galangin-whey protein-nanoparticles
XUE Xiaofei1 , DONG Pengyuan2 , XU Mengya3 , WANG Panpan4
Affiliations
1 Zhengzhou Health College, Zhengzhou 450064, China;
doi: 10.7501/j.issn.0253-2670.2026.18.021
文章导航
目的 制备高良姜素-乳清蛋白纳米粒（galangin-whey protein-nanoparticles，Gal-WP-NPs），考察其体内口服药动学行为及其对肝缺血再灌注损伤的保护作用。方法 单因素实验考察各个处方工艺对Gal-WP-NPs的影响。采用Box-Behnken设计-效应面法（Box-Behnken design-response surface methodology，BBD-RSM）得到Gal-WP-NPs最优处方工艺，测定Gal-WP-NPs包封率、载药量、粒径及ζ电位等。冷冻干燥法制备Gal-WP-NPs粉末，透射电子显微镜（transmission electron microscope，TEM）观察Gal-WP-NPs微观形貌，X射线粉末衍射（X-ray powder diffraction，XRPD）法分析Gal-WP-NPs中高良姜素晶型。比较高良姜素及Gal-WP-NPs溶解度，考察Gal-WP-NPs模拟胃肠液中的释药行为。按150 mg/kg（以高良姜素计）ig给予SD大鼠高良姜素和Gal-WP-NPs，计算主要药动学参数及Gal-WP-NPs相对生物利用度。建立SD大鼠肝脏缺血再灌注模型，比较高良姜素和Gal-WP-NPs对肝缺血再灌注损伤的保护作用。结果 Gal-WP-NPs最佳处方工艺：反溶剂相与溶剂相体积比为15.40∶1，乳清蛋白与高良姜素用量比为15.05∶1，超声功率为82.00 W。Gal-WP-NPs包封率、载药量、粒径和ζ电位分别为（94.07±0.98）%、（5.76±0.09）%、（197.39±4.46）nm和（-23.79±0.75）mV。Gal-WP-NPs呈类球形纳米粒，高良姜素在Gal-WP-NPs粉末中以无定形状态存在，溶解度得到极显著提高（P ＜0.01），Gal-WP-NPs体外释药行为符合Weibull模型。Gal-WP-NPs达峰时间（t max）延后至（2.17±0.64）h，半衰期（t ₁/₂）增加至（5.11±0.95）h，口服相对生物利用度提高至6.58倍。Gal-WP-NPs极大提高了高良姜素对肝缺血再灌注损伤的保护作用。结论 Gal-WP-NPs显著增加了高良姜素口服相对生物利用度，增强了高良姜素对对肝缺血再灌注损伤的保护作用。
高良姜素
/
乳清蛋白
/
纳米粒
/
Box-Behnken设计-效应面法
/
药动学
/
生物利用度
/
肝缺血再灌注损伤
Objective To prepare galangin-whey protein-nanoparticles (Gal-WP-NPs), and study its oral pharmacokinetic behavior and protective effect on the hepatic ischemia reperfusion injury in vivo . Methods Single-factor experiments were conducted to investigate the effects of various formulation processes on Gal-WP-NPs. Box-Behnken design-response surface methodology (BBD-RSM) was used to obtain its optimal prescriptions. Entrapment efficiency, drug loading, particle size and ζ potential were determined. Gal-WP-NPs powder was prepared by freeze-drying method. Transmission electron microscopy (TEM) was used to observe the microstructure of Gal-WP-NPs. Galangin crystal in Gal-WP-NPs powder was analyzed by X-ray powder diffraction (XRPD). Solubility of galangin and Gal-WP-NPs powder were compared, and drug release behavior of Gal-WP-NPs in gastrointestinal fluid was determined. SD rats were administered galangin and Gal-WP-NPs via ig at a dose of 150 mg/kg (calculated as galangin), the main pharmacokinetic parameters and relative bioavailability of Gal-WP-NPs were calculated. The model of hepatic ischemia reperfusion injury was established, and then the protective effects of galangin and Gal-WP-NPs were compare on the hepatic ischemia reperfusion injury. Results Optimal formulation processes of Gal-WP-NPs: the volume ratio of the anti-solvent phase to the solvent phase was 15.40:1, the amounts ratio of whey protein to galangin was 15.05:1, and the ultrasonic power was 82.00 W. Envelopment efficiency, drug loading, particle size and ζ potential were (94.07 ± 0.98)%, (5.76 ± 0.09)%, (197.39 ± 4.46) nm and (-23.79 ± 0.75) mV, respectively. Gal-WP-NPs are spherical nanoparticles. Galangin existed as an amorphous state in Gal-WP-NPs powder. Solubility of galangin was significantly increased (P < 0.01), and the release process of Gal-WP-NPs in vitro conformed to the Weibull model. The peak time (t max ) of Gal-WP-NPs was delayed to (2.17 ± 0.64) h, half-life period (t 1/2 ) was increased to (5.11 ± 0.95) h, and oral relative bioavailability was increased to 6.58 times. Gal-WP-NPs significantly enhanced the protective effect of galangin on the hepatic ischemia reperfusion injury. Conclusion Gal-WP-NPs significantly increased the oral relative bioavailability of galangin and enhanced the protective effect on the hepatic ischemia reperfusion injury.
galangin
/
whey protein
/
nanoparticles
/
Box-Behnken design-response surface methodology
/
pharmacokinetics
/
bioavailability
/
hepatic ischemia reperfusion injury
薛晓菲, 董鹏远, 许梦雅, 王盼盼.
高良姜素-乳清蛋白纳米粒的制备、药动学及其对肝缺血再灌注损伤的保护作用.
中草药,
2026
, 57
(18)
: 7334
-7346
.
DOI: 10.7501/j.issn.0253-2670.2026.18.021
XUE Xiaofei, DONG Pengyuan, XU Mengya, WANG Panpan.
Preparation, pharmacokinetics and protective effect on hepatic ischemia reperfusion injury of galangin-whey protein-nanoparticles[J].
Chinese Traditional and Herbal Drugs ,
2026
, 57
(18)
: 7334
-7346
.
DOI: 10.7501/j.issn.0253-2670.2026.18.021
参考文献
引证文献
李东良, 周晓玲, 敖秀兰. 间接型药物性肝损伤: 新类型与新挑战[J]. 药物评价研究, 2024, 47(5): 921-926.
2026年第57卷第18期
PDF下载
34
6
引用本文
BibTeX
文章信息
doi: 10.7501/j.issn.0253-2670.2026.18.021
接收时间：2026-03-24
首发时间：2026-10-29
https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.18.021
引用本文
BibTeX
2种不同金属材料的力学参数
科 属数 种数 占总种数比例 属 种数 占总种数比例 鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78 小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39 多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39 红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87 小菇属 Mycena 11 5.26 光柄菇属 Pluteus 5 2.39 红菇属 Russula 17 8.13 栓菌属 Trametes 5 2.39
关闭全屏
BibTeX
EndNote
RefWorks
TxT
PDF下载
全屏
34
6
关闭全屏
北京市海淀区学院南路86号
010-62662699（运营及技术支持）
qkjq@cast.org.cn
